Multiple Myeloma
VIDEO: Multiple myeloma developments for newly diagnosed, relapsed or refractory patients
In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the new wave of novel therapeutics on the market to treat multiple myeloma.
Race, age linked to delayed treatment with oral antimyeloma therapies
The timing with which patients with newly diagnosed multiple myeloma began treatment with oral antimyeloma medications varied greatly by age and race, according to retrospective study results.
Novel technique may provide ‘incredible’ benefit to CAR T-cell therapy
A novel therapeutic approach may improve the persistence and functionality of chimeric antigen receptor T cells, helping to prevent relapse.
SGLT2s could prevent cardiotoxic effects of cancer therapies in patients with diabetes
SGLT2 inhibition may prevent cancer therapy-related cardiac dysfunction and improve other outcomes in patients with diabetes undergoing cancer therapy, researchers reported.
FDA approves isatuximab-irfc combination for certain adults with multiple myeloma
The FDA approved isatuximab-irfc in combination with bortezomib, lenalidomide and dexamethasone for treatment of certain adults with multiple myeloma.
Risk for second primary malignancies no greater with CAR-T than other standard therapies
Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.
FDA approves IND application for Eque-cel T-cell therapy in SLE, lupus nephritis
The FDA has approved an investigational new drug application for Eque-cel, an autologous T-cell injection, in patients with systemic lupus erythematosus and lupus nephritis, according to a press release from the manufacturer.
Three women junior faculty named NCI K12 faculty scholars
Three Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine women junior faculty members have been named NCI K12 2024 faculty scholars.
Findings highlight ‘critical importance’ of infectious complications after CAR-T
Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.